Member Info for Alpha-dog

Great post. Very relevant. Clearly big market still for covid therapeutics.

https://www.science.org/content/article/was-study-created-hybrid-covid-19-virus-too-risky
I don’t have any personal perspective on origins of original covid 19 virus but this work is fairly terrifying both from concern re: escape from lab but also that recombinants are occurring naturally.

Is synairgen the only share where chat outnumbers trades? Light hearted observation on very low volumes.

https://www.lse.co.uk/rns/SNG/home-cohort-data-of-sg016-phase-ii-trial-9cdbtkvdgmg48k9.html
Team synairgen conducted interesting and thorough pooled analysis- announced in April 2021. See link above. Worth a re-read. I fully expect a pooled analysis of the home trials. With some back of the envelope calculations we can be absolutely confident that this will be statistically significant and startlingly effective. At some point this will be reflected in SP. There may even be enough safety and efficacy data for regulatory authorities. No weird endpoints for SNG, like 6 hrs in ED. Straightforward admitted or not. There is also the teasing prospect of targeting on clinical parameters eg breathlessness.

https://amp.dw.com/en/new-german-covid-19-rules-come-into-force-as-infections-rise-in-colder-months/a-63305695
We have, as of end of September, abandoned asymptomatic testing of NHS staff and patients. These and other measures including N95 mask wearing introduced in Germany on the evidence of Autumn wave starting introduced the very next day. The irony of this is painful and a little terrifying. UK is flying blind once again when others are sharpening their defences.

I’m certainly up for that. It would require a little work to pull together all the relevant data but it is all listed as RNSs on Synairgen ‘s website. A back of the envelope pulling of at home and A2P2 data and pooling of phase 2 and Sprinter needed. Summary of exploratory subgroup analysis from recent RNSs too.
Who knows it could get a parliamentary question perhaps from the right honorable MP for Southampton.
The meta-analysis to be properly done would need Synairgen to support in the form of individual patient level data.

Here here Titania. Couldn’t agree more. How does this get to those who advise on these things? CMO, chief scientist, MHRA, COBRA?

https://www.ecdc.europa.eu/en/publications-data/download-data-hospital-and-icu-admission-rates-and-current-occupancy-covid-19
This is probably the best source of reliable data from Europe.

I spotted this difference yesterday. Not certain whether it is of any significance or if difference between Synairgen uk listing and US is simply related to volume.

I meant market valuation sun £40m

This is great news and nice work. The populations of participants look broadly similar- within 7 days of symptom onset. Pooling likely therefore valid. We would need to see the data on participant details but that will come.
I’m surprised SP response so muted. It’s still well below level when last good news broke! Such is market sentiment at the moment. The greater question is who would sell with market valuations at these levels- sub £40. The potential market is huge. Paxlovid data is for

Answer to chi-sq question. It comes down to stats. Chi-sq used for categorical variables. It’s a no-nonsense test and tells me they didn’t use any statistical jiggery pokery to find the statistically significant results.

Muted SP response so far. Incredible data. First and to date only positive long covid data. As a board and LTHs we should be tweeting and re-tweeting on covid and long covid boards/forums.

I may be wrong but I think that one issue for the big orders was that ITM didn’t have the 5 mw electrolyser up and going. I was slightly disconcerted when ITM got a £9m grant 3-4 months ago to develop this. Looks like strategically they should have had this totally sorted before massive upscale of capacity. Once it is proven I’m hoping some bigger orders will come. Meantime hold and hope.
Possible takeover target?

https://hydrogen-central.com/linde-build-35-megawatt-pem-proton-exchange-membrane-electrolyzer-produce-green-hydrogen-niagara-falls-new-york/
Surely this will be ITM supplying the electrolyser. Modest scale but hopefully a signal of confidence.

My view of this is that is really raising the profile of synairgen and treatment of acute respiratory viral infections generally. It won’t support EUA or full authorisation but may help better define the scale of the problem.
Certainly good to be involved with but not a game changer. Potentially another building block in the scientific base though and good publicity.

Neon- I agree.
I’m perplexed why uk and European governments are so behind the curve on this. It was evident from the very first day of Ukraine invasion that governments should be on an energy war footing and actively sourcing and scaling green hydrogen/renewables on a massive scale.
The low hanging fruit is immediate scaling of green H2 and replacing all ammonia products and all other industrial processes that currently use grey H2 with green. Other relatively easy action is green H2 blend in heating.
We are nowhere near where we could have been in terms of green H2 displacing grey.
Probably a trillion euros across Europe supporting people to pay inflated gas/energy prices this year alone that could have been better spent on immediate rapid upscale of green H2 and reducing gas demand.

Dr Eric Fiegel-Ding might be useful to follow for updates on this story.

https://twitter.com/drericding/status/1565412571385139202?s=21&t=TeK3XhzUXygHHUHtubktyg

I’m with you Mr Costs. All the evidence points to SNG being really very effective. Virus and variant agnostic. Possibly even working in combination with other therapies. I will just need to be patient. Playing the ups and downs of sentiment very high risk strategy. Board is at its best when digging out research and evidence.
My best memory from this board was the good Dr from Kansas who slipped up and let news of progression to P3 out of the bag. It took 3-4 months from then to get confirmation. ACTIV2 results seem to be similarly slow. They may help point to where SNG is best targeted. I recall SHH saying that he thought best targeted in very high risk populations to prevent admission. ACTIV2 may support that. I’m all in and staying in.

I can’t find any mention of anything either. Hopefully just market sentiment/wobble.